Amdipharm Mercury (Australia)

Company snapshot

Amdipharm Mercury (Australia) is a pharma organization headquartered in AU. NovaPharmaNews links 0 clinical program(s), 11 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 6 approved product(s) across US/EU regulatory metadata.

Public regulatory, clinical, patent, and corporate records for Amdipharm Mercury (Australia). Not investment advice.

• deal Jun 4, 2026

  Mercury Acquires King Courier to Grow Bay Area Logistics: Deal Intelligence for Pharma Teams

• What is Amdipharm Mercury (Australia)?

  Amdipharm Mercury (Australia) is a pharma organization headquartered in AU. NovaPharmaNews links 0 clinical program(s), 11 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• Is Amdipharm Mercury (Australia) publicly traded?

  Amdipharm Mercury (Australia) appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Amdipharm Mercury (Australia) develop or market?

  We link 11 drug profile(s) where Amdipharm Mercury (Australia) is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/amdipharm-limited#company-drugs.

• What are the latest developments for Amdipharm Mercury (Australia)?

  Browse related news and pipeline sections on this page for coverage and ClinicalTrials.gov-linked program updates.

• What therapeutic areas does Amdipharm Mercury (Australia) focus on?

  No specific therapeutic focus areas are currently identified for Amdipharm Mercury (Australia) in our database.